Trial Profile

A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
Indications Ulcerative colitis
Focus Pharmacokinetics
Acronyms SHINE1
Sponsors Eli Lilly and Company

Most Recent Events

17 Oct 2023 Results (N=26) accessing safety and efficacy of Mirikizumab as induction therapy in paediatric patients with moderately to severely active ulcerative colitis presented at the 31st United European Gastroenterology Week.
09 May 2023 According to an Eli Lilly and Company media release, interim data from this trial were presented at Digestive Disease Week (DDW) 2023.
26 Apr 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com